Is EXEL or DFTX the better stock?

EXEL scores higher: EXEL 73.9, DFTX 17.0 out of 100 on the Bull Rankings quality-growth score, which blends business quality, growth and valuation into one number. A higher score means a stronger business at a more reasonable price — it is not a price target or a recommendation.

Where do EXEL and DFTX differ most?

The widest gap is quality, where EXEL leads by 76 points on the 0–100 pillar scale. EXEL leads all three pillars, so the gap is broad rather than a single-measure difference.

How are EXEL and DFTX scored?

Each carries the same 0–100 quality-growth score used everywhere on the site, built from three pillars — quality (profitability and returns on capital), growth (revenue and earnings), and value (what you pay for them) — combined as a geometric mean, so a weak pillar cannot be papered over by a strong one.

How current is this comparison?

The whole universe is re-scored every trading day after the US market close, so the scores and fundamentals here reflect the latest published edition.

COMPARE · Data as of August 27, 2026

DFTX vs EXEL

Verdict: Side-by-side breakdown using the Bull Rankings model. DFTX scored 17.0, EXEL scored 73.9 — EXEL leads.

Compare another set

DFTX

Definium Therapeutics, Inc.

Biotechnology · Quality-Growth

$43.82 · $5.9B

fundamentals as of Jun 2026

Score gap

56.9

EXEL leads

EXEL

Exelixis, Inc.

Biotechnology · Quality-Growth

73.9

$56.72 · $14.1B

fundamentals as of Jul 2026

At a glance · who leads each dimension, on the model's own rules

Strongest balance sheetDFTX0.04
Highest qualityEXEL97 / 100
Largest discount to fair valueEXEL-39%

Side by side · every name on one set of axes

The model, pillar by pillar (0–100 each)

DFTX

stronger →← stronger

EXEL

Qualityreturns · margins · balance sheet

Growthrevenue & earnings expansion

Valuevaluation vs sector peers

EXEL is stronger on 3 of 3 pillars.

Fundamentals, head-to-head

DFTX

EXEL

-$168mF

FCF

$1.2bC+

—

Rev

+9.2%B

0.04A-

D/E

0.09B+

—

PEG

2.56C

—

P/E

17.8xA-

Winner per row is the stronger grade; where grades tie, the better figure breaks it. A true tie or a missing value shows no highlight.

Valuation · DCF cross-check

DFTX

EXEL

—

Price vs fair valuelower is cheaper

39% below

—

Growth the price implies10-yr FCF · lower = less priced in

~-2%/yr

—

1-yr DCF upside

+38%

—

5-yr DCF upside

+64%

—

10-yr DCF upside

+108%

The DCF is a cross-check on intrinsic value, separate from the quality-growth score above.

Model signals

DFTX

Why this score

Diluting shareholders

EXEL

Why this score

Buying back stock
Durable high returns

The companies

DFTXDefinium Therapeutics, Inc.

Biotechnology · $43.82 · beta 2.26

Why now

Biotechnology · market cap $5.9b. 12% off the 52-week high of $49.70. 17 sell-side analysts rate this a Strong Buy with a mean 1-yr target of $67.47 (implying +54% upside).

Moat

Pharma moat is patent runway + pipeline depth — a single approved molecule funds the next generation of bets. Late-stage trials carry binary readouts that swing valuation 30%+.

Risk

Free cash flow is negative (-$168m) — capital raises or debt issuance likely required; dilution / leverage risk. Beta 2.26 implies above-market volatility — position-size to the drawdowns this name will produce in a market correction, not to its bull-case return. ROE -39% is below the long-run sustainable threshold of ~10% — capital efficiency would need to improve for the equity base to compound at the market rate.

EXELExelixis, Inc.

Biotechnology · $56.72 · beta 0.42

Why now

Biotechnology · market cap $14.1b. Trading near 52-week high of $57.57 — momentum setup, limited technical margin of safety. 17 sell-side analysts rate this a Buy with a mean 1-yr target of $53.00 (implying -7% upside).

Moat

Net margin 35% is exceptional — pricing-power territory rare outside premium software, branded staples, and specialty pharma. ROE 47% — top-decile capital efficiency. Either pricing leverage, low capital intensity, or aggressive buybacks; the durability story depends on which. FCF converts 136% of net income — earnings translate cleanly into cash, a sign that working capital and capex are well-disciplined.

Risk

Trading within 1% of the 52-week high — limited technical margin of safety; a momentum reversal would test conviction. Trial-readout binary — late-stage clinical trials carry approve/reject outcomes that swing valuation 30%+; the equity is effectively a portfolio of these binary events, not a steady cash-flow business.

Verdict — model-derived comparison

Generating verdict… typically 5–10 seconds

Not investment advice. The Bull Rankings publishes a quantitative ranking model and accompanying analysis for general informational purposes only. Nothing on this page is a recommendation to buy, sell, or hold any security; nothing is personalized to your circumstances, risk tolerance, or tax situation. Investing carries the risk of loss — invest at your own risk and consider consulting a licensed financial professional before acting on anything you read here. See terms and methodology for full disclosures.

Where DFTX and EXEL diverge

On the headline score the gap is 56.9 points in favor of EXEL. The widest single difference is Quality, where EXEL leads by 75.8 points.

QualityDFTX 21.0 · EXEL 96.8EXEL +75.8
GrowthDFTX 10.0 · EXEL 80.0EXEL +70.0
ValueDFTX 23.2 · EXEL 52.2EXEL +29.0

Pillars run 0–100 against sector peers, so a score is a statement about a company relative to its own industry rather than to the other name here. A wide Value gap usually means the market already prices the difference in quality or growth — which is the trade-off this comparison comes down to.